GEP20043356B - Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor - Google Patents

Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor

Info

Publication number
GEP20043356B
GEP20043356B GE4893A GEAP2001004893A GEP20043356B GE P20043356 B GEP20043356 B GE P20043356B GE 4893 A GE4893 A GE 4893A GE AP2001004893 A GEAP2001004893 A GE AP2001004893A GE P20043356 B GEP20043356 B GE P20043356B
Authority
GE
Georgia
Prior art keywords
adrenoceptor
alpha
prevention
treatment
compounds useful
Prior art date
Application number
GE4893A
Other languages
English (en)
Inventor
Siegfried Wurster
Mia Engstroem
Liisa Huovinen
Sari Kalliokoski
Leila Kelanne
Eeva Liisa Savola
Original Assignee
Juvantia Pharma Ltd Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20000303A external-priority patent/FI20000303A0/fi
Application filed by Juvantia Pharma Ltd Oy filed Critical Juvantia Pharma Ltd Oy
Publication of GEP20043356B publication Critical patent/GEP20043356B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
GE4893A 2000-02-11 2001-02-07 Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor GEP20043356B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18202100P 2000-02-11 2000-02-11
FI20000303A FI20000303A0 (fi) 2000-02-14 2000-02-14 Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet

Publications (1)

Publication Number Publication Date
GEP20043356B true GEP20043356B (en) 2004-04-13

Family

ID=26160944

Family Applications (1)

Application Number Title Priority Date Filing Date
GE4893A GEP20043356B (en) 2000-02-11 2001-02-07 Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor

Country Status (22)

Country Link
EP (1) EP1253926A1 (xx)
JP (1) JP2003522148A (xx)
KR (1) KR20020080413A (xx)
AU (1) AU780802B2 (xx)
BR (1) BR0108221A (xx)
CA (1) CA2399421A1 (xx)
CZ (1) CZ20022884A3 (xx)
EA (1) EA200200846A1 (xx)
EE (1) EE200200435A (xx)
GE (1) GEP20043356B (xx)
HR (1) HRP20020746A2 (xx)
HU (1) HUP0300032A3 (xx)
IL (1) IL151017A0 (xx)
IS (1) IS6476A (xx)
MX (1) MXPA02007454A (xx)
MY (1) MY133957A (xx)
NO (1) NO20023773D0 (xx)
NZ (1) NZ520500A (xx)
PL (1) PL357872A1 (xx)
SK (1) SK11472002A3 (xx)
WO (1) WO2001058454A1 (xx)
YU (1) YU59102A (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
NZ530366A (en) * 2001-07-20 2005-02-25 Juvantia Pharma Ltd Oy Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416432D0 (en) * 1984-06-28 1984-08-01 Wyeth John & Brother Ltd Benzoquinolizines
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6150389A (en) * 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents

Also Published As

Publication number Publication date
CA2399421A1 (en) 2001-08-16
SK11472002A3 (sk) 2003-02-04
HRP20020746A2 (en) 2004-12-31
HUP0300032A2 (en) 2003-05-28
EP1253926A1 (en) 2002-11-06
HUP0300032A3 (en) 2006-01-30
IL151017A0 (en) 2003-02-12
JP2003522148A (ja) 2003-07-22
EA200200846A1 (ru) 2002-12-26
AU3551001A (en) 2001-08-20
YU59102A (sh) 2005-11-28
IS6476A (is) 2002-07-19
EE200200435A (et) 2003-12-15
NO20023773L (no) 2002-08-09
AU780802B2 (en) 2005-04-21
MY133957A (en) 2007-11-30
BR0108221A (pt) 2003-03-05
NZ520500A (en) 2005-01-28
KR20020080413A (ko) 2002-10-23
WO2001058454A1 (en) 2001-08-16
MXPA02007454A (es) 2004-08-23
PL357872A1 (en) 2004-07-26
CZ20022884A3 (cs) 2003-02-12
NO20023773D0 (no) 2002-08-09

Similar Documents

Publication Publication Date Title
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
CA2427227A1 (en) Lactam compound
MA28009A1 (fr) Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques
WO2003048164A3 (en) Adenosine a2a receptor antagonists
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
CA2468649A1 (en) Adenosine a2a receptor antagonists
SE9901573D0 (sv) New compounds
GB0130677D0 (en) Medicaments and novel compounds
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis
SE9901572D0 (sv) New compounds
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor
GEP20043377B (en) Pharmaceutical Complex
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
MY131159A (en) New pharmaceutical compositions containing epinastine and pseudoephedrine
EA200100876A2 (ru) Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12
ATE477021T1 (de) 1,3,5-triazepin-dionen zur behandlung von malaria
ATE301997T1 (de) Antivirale therapie
ATE270886T1 (de) Antivirale therapie